Marco LLM - CureVac NV G Counsel

5CV Stock  EUR 2.49  0.09  3.75%   

Insider

Marco LLM is G Counsel of CureVac NV
Phone49 7071 9883 0
Webhttps://www.curevac.com

CureVac NV Management Efficiency

The company has return on total asset (ROA) of (0.3424) % which means that it has lost $0.3424 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1851) %, meaning that it generated substantial loss on money invested by shareholders. CureVac NV's management efficiency ratios could be used to measure how well CureVac NV manages its routine affairs as well as how well it operates its assets and liabilities.
CureVac NV has accumulated 55.28 M in total debt with debt to equity ratio (D/E) of 0.08, which may suggest the company is not taking enough advantage from borrowing. CureVac NV has a current ratio of 5.5, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist CureVac NV until it has trouble settling it off, either with new capital or with free cash flow. So, CureVac NV's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CureVac NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CureVac to invest in growth at high rates of return. When we think about CureVac NV's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Christopher LohmannTalanx AG
55
Harry KanwarSuperior Plus Corp
N/A
Edgar PulsTalanx AG
50
Rick CarronSuperior Plus Corp
N/A
Robert GreenSIVERS SEMICONDUCTORS AB
60
David BullockOrigin Agritech
49
Leigh DowIdentiv
N/A
Dag SigurdSIVERS SEMICONDUCTORS AB
73
Larry CordellOrigin Agritech
56
Caroline SchlienkampTalanx AG
49
Bjorn NorrbomSIVERS SEMICONDUCTORS AB
72
Yasheng YangOrigin Agritech
51
Mike TaylorIdentiv
N/A
Christina HickieCSL Limited
N/A
MBA MBASuperior Plus Corp
70
CCLP CMASuperior Plus Corp
62
Tomas DuffySIVERS SEMICONDUCTORS AB
62
BCom BCommCSL Limited
57
FCA FCASuperior Plus Corp
68
JeanJacques HenchozTalanx AG
59
James DevensSuperior Plus Corp
N/A
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. CUREVAC N operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 455 people. CureVac NV (5CV) is traded on Frankfurt Exchange in Germany and employs 764 people.

Management Performance

CureVac NV Leadership Team

Elected by the shareholders, the CureVac NV's board of directors comprises two types of representatives: CureVac NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CureVac. The board's role is to monitor CureVac NV's management team and ensure that shareholders' interests are well served. CureVac NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CureVac NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pierre BSc, CFO MD
Ulrike MD, Sr Officer
Slavica StevanovicHeck, Head HR
Thorsten Schuller, Head Communications
Igor MSc, Chief Board
Antony Blanc, Chief MD
Malte Greune, Member COO
Sarah Fakih, VP Relations
LLM LLM, Member CEO
Marco LLM, G Counsel

CureVac Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CureVac NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in CureVac Stock

When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in CureVac Stock please use our How to Invest in CureVac NV guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.